Healthcare services provider BrightSpring Health Services (NASDAQ: BTSG) will be announcing earnings results tomorrow before market open. Here’s what to expect.
BrightSpring Health Services beat analysts’ revenue expectations by 1.1% last quarter, reporting revenues of $3.05 billion, up 28.6% year on year. It was a mixed quarter for the company, with a decent beat of analysts’ EPS estimates but full-year EBITDA guidance missing analysts’ expectations.
Is BrightSpring Health Services a buy or sell going into earnings? Read our full analysis here, it’s free.
This quarter, analysts are expecting BrightSpring Health Services’s revenue to grow 6.8% year on year to $2.75 billion, slowing from the 27% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.09 per share.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. BrightSpring Health Services has a history of exceeding Wall Street’s expectations, beating revenue estimates every single time over the past two years by 4.8% on average.
Looking at BrightSpring Health Services’s peers in the healthcare providers & services segment, some have already reported their Q1 results, giving us a hint as to what we can expect. Option Care Health delivered year-on-year revenue growth of 16.3%, beating analysts’ expectations by 6.1%, and Chemed reported revenues up 9.8%, topping estimates by 0.8%. Option Care Health traded down 2% following the results while Chemed was also down 6.9%.
Read our full analysis of Option Care Health’s results here and Chemed’s results here.
Questions about potential tariffs and corporate tax changes have caused much volatility in 2025. While some of the healthcare providers & services stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 4.4% on average over the last month. BrightSpring Health Services is down 3.6% during the same time and is heading into earnings with an average analyst price target of $24.41 (compared to the current share price of $17.53).
When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we’ve found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback.
